NCT01649271 2025-02-11
Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.
Boehringer Ingelheim
Phase 1 Completed
Clinical Trials
8 trialsNCT00950742 2025-02-10
Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With HerceptinĀ® in Patients With HER2-positive Advanced Breast Cancer.
Boehringer Ingelheim
Phase 1 Completed
NCT01125566 2019-07-18
LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment
Boehringer Ingelheim
Phase 3 Completed
NCT01441596 2015-09-07
Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases
Boehringer Ingelheim
Phase 2 Completed
NCT00431067 2014-06-09
Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy
Boehringer Ingelheim
Phase 2 Completed
NCT00425854 2013-12-31
An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-negative Metastatic Breast Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT00826267 2013-12-31
6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab
Boehringer Ingelheim
Phase 2 Completed
NCT00708214 2013-12-30
BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer
Boehringer Ingelheim
Phase 2 Completed